UNIONDALE, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION, founded in 1998, is a mid-sized nonprofit in the Human Services sector that reported $37.2M in total revenue in fiscal year 2024. Revenue surged 63% from the prior year, signaling strong growth momentum. The organization ran a surplus of $10.0M, a strong 27% operating margin.
THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD.THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. THROUGH FY25, THE LUSTGARTEN FOUNDATION HAS INVESTED $301 MILLION IN PANCREATIC CANCER RESEARCH.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $37,190,710 | $22,749,028 | +0.6% |
| Expenses | $27,180,092 | $30,962,554 | -0.1% |
| Net Income | $10,010,618 | $-8,213,526 | -2.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ANDREW LUSTGARTEN | CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ROBERT F VIZZA | CHAIRMAN EMERITUS | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JENNIE FORTUNOFF | SECRETARY | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| PHILIP D'AMBROSIO | TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ADAM SILVER | VICE CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| SOMMER BAZURO PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JOHN H COBB | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JESSICA LUSTGARTEN COURTEMANCHE | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MARCIA LUSTGARTEN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SHEILA MAHONY | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| CHARLES R SCHUELER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| WILLA SHALIT | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SCOTT PENBERTHY | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SELWYN VICKERS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| AARON KANTOFF | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| RICHARD R BARAKAT MD MBA | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| LINDA TANTAWI | CEO | 40.00 |
Officer
|
$489,273 | $39,510 | $528,783 |
| KERRI KAPLAN | PRESIDENT | 40.00 |
Officer
|
$341,967 | $40,938 | $382,905 |
| FAISAL JAWAID | CFO | 40.00 |
Officer
|
$287,237 | $41,045 | $328,282 |
| ANDREW RAKEMAN | VP RESEARCH | 40.00 |
Highest
|
$272,473 | $41,720 | $314,193 |
| GLEN PECK | SVP TECHNOLOGY & BUSINESS INTELLIGENCE | 40.00 |
Highest
|
$268,413 | $39,490 | $307,903 |
| JACLYN P LYMAN | HEAD CLINICAL RESEARCH & DEVELOPMENT | 40.00 |
Highest
|
$258,870 | $21,280 | $280,150 |
| STEPHANIE DERGARABEDIAN | NATIONAL DIRECTOR OF DEVELOPMENT | 40.00 |
Highest
|
$179,133 | $35,668 | $214,801 |
| SUSAN M JACOBSON | DIRECTOR EXTERNAL & COMMUNITY RELATIONS | 40.00 |
Highest
|
$166,081 | $20,129 | $186,210 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $37,190,710 | $27,180,092 | $91,535,774 | $10,010,618 |
| 2024 | $22,749,028 | $30,962,554 | $75,802,153 | $-8,213,526 |
| 2023 | $18,297,575 | $28,681,699 | $78,560,475 | $-10,384,124 |
| 2022 | $30,446,505 | $33,834,657 | $78,505,397 | $-3,388,152 |
| 2021 | $24,467,833 | $21,726,029 | $96,561,632 | $2,741,804 |
| 2020 | $14,966,634 | $24,862,781 | $90,551,380 | $-9,896,147 |
| 2019 | $29,500,163 | $29,535,726 | $99,323,748 | $-35,563 |
Compare MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION with other nonprofits in New York and across the country.